The aim of this study is to examine the expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer Immunohistochemistry and bioinformatics investigation were directed to assess YAP1 articulation levels during PCa inception and movement. YAP1 articulation was available in the basal epithelial cells in considerate prostatic tissues, lost in second rate PCa, however raised in high-grade prostate adenocarcinomas. Curiously, the statement of YAP1 was diminished/lost in both human and mouse NEPC. After long haul androgen hardship treatment, 25–30% prostate cancer (PCa) procures a forceful neuroendocrine (NE) aggregate. Dysregulation of YAP1, a key record coactivator of the Hippo pathway, has been identified with malignant growth movement. Notwithstanding, its part in neuroendocrine prostate malignancy (NEPC) has not been surveyed. Hence the primary aim of observing and examining the expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer, was achieved.
Reference link- https://www.nature.com/articles/s41391-020-0229-z
